Under the "dual carbon" goal, there is still much room for improvement in the carbon reduction and emission reduction of pharmaceutical equipment

【Pharma.
com Market Analysis】In September 2020, China proposed the goal of double carbon (that is, the abbreviation of carbon peak and carbon neutrality): carbon peak before 2030 and carbon neutrality
before 2060 。 Recently, the "Opinions on the Complete, Accurate and Comprehensive Implementation of the New Development Concept to Do a Good Job in Carbon Peaking and Carbon Neutrality" further clarifies: By 2025, GDP energy consumption will be reduced by 13.
5% compared with 2020, and GDP carbon dioxide emissions will be reduced by 18% compared with 2020; By 2030, GDP carbon dioxide emissions will be reduced by more than 65% compared with 2005, and carbon dioxide emissions will peak and achieve a stable reduction; By 2060, a series of ambitious goals
such as carbon neutrality will be successfully achieved.
Implementing the "dual carbon" strategy and taking the road of green and low-carbon has become the main keynote
of China's high-quality economic development.
Under the "double carbon" goal, how to effectively mobilize the strength of enterprises to promote carbon reduction and emission reduction has also become a topic
of concern for enterprises in the current pharmaceutical equipment industry.
Under the "double carbon" goal, there is still much room for improvement in the carbon reduction and emission reduction of pharmaceutical equipment (Image source: Pharma.
com) In recent years, China's pharmaceutical industry has developed rapidly, accompanied by the huge consumption of water, electricity, gas, fuel, raw materials and other resources, as well as environmental pollution in the pharmaceutical process, etc.
, the national level has long advocated the concept of low-carbon environmental protection and sustainable development, and introduced the "environmental protection tax", in this context, pharmaceutical factories gradually realize the importance of carbon reduction and emission reduction of pharmaceutical equipment, and the requirements for equipment are improved.
Forcing the pharmaceutical equipment industry to update environmental protection technology and upgrade processes
.
The application of carbon reduction and emission reduction technology of pharmaceutical equipment can greatly reduce the cost of raw materials and electrical energy in pharmaceutical production, as well as the cost of environmental protection, while avoiding environmental pollution problems, and helping to improve the production efficiency and economic benefits
of pharmaceutical companies.
"From the perspective of pharmaceutical companies, we have launched a series of double-effect and three-effect energy-saving concentrators, which reduce energy consumption by 50% and 70% respectively compared with single-effect energy-saving concentrators, and enterprises can recover all the investment
in this concentrator from energy-saving fees in less than a year.
" Some pharmaceutical equipment companies said
so.
There are also pharmaceutical equipment companies that have launched a new type of combined multi-effect water distillation machine that saves energy and reduces consumption, which can run continuously for 240 days and save 65%
of comprehensive energy in saving water, saving industrial steam, and reducing the sewage pressure of enterprises.
In addition, the technology used in the machine can save 21 million tons of standard coal and 340 million tons of drinking water every year, which can help pharmaceutical companies greatly reduce environmental protection pressure
.
Judging from the feedback from some pharmaceutical manufacturers that have applied carbon reduction and emission reduction technology, these upgraded equipment undoubtedly bring great value to pharmaceutical companies and help pharmaceutical companies achieve the win-win goal
of economic and social benefits.
However, some industry insiders pointed out that there are also shortcomings in the current carbon reduction and emission reduction of pharmaceutical equipment, which are mainly reflected in actual
implementation.
For example, the carbon reduction and emission reduction measures adopted by many pharmaceutical companies are implemented only after the completion of drug production, mainly for the treatment of waste and pollutants after drug production, and then control pollution, rather than running carbon reduction and emission reduction measures into all aspects of
drug production.
As a result, although pharmaceutical companies have met the standards for reducing pollutant emissions, they have not fundamentally realized comprehensive carbon reduction and emission reduction measures for
equipment.
Therefore, the industry believes that there is still much room for
improvement in the carbon reduction and emission reduction of pharmaceutical equipment.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.